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v The protein kinase-C (PKC) second messenger system contributes to regulation of cell growth and 
differentiation. This study was undertaken to examine the effects of modulators of the PKC enzyme system 
on the state of differentiation and proliferation rates of human gliomas in vitro. The administration of the 
PKC-activating phorbol esters 4-beta-phorbol-12,13-dibutyrate (PDB) and phorbol-12-myristate-13-acetate 
(PMA) resulted in a dose-related inhibition of growth of human glioma cell lines in vitro as measured by 3H_ 
thymidine uptake. The synthetic nonphorbol PKC activator (SC-9) produced an even more pronounced 
decrease of 3H-thymidine uptake. Diacylglycerol, an endogenous activator of the system, applied externally, 
transiently decreased the proliferation, "in concordance with its short-lived existence in vivo. Conversely, the 
administration of 4-alpha-phorbol-12, 13-didecanoate (a-PDD), a phorbol ester that binds but does not activate 
the enzyme, had no effect on the proliferation rate. At the dosages that maximally decreased proliferation, 
there was no evidence of direct glioma cell lysis induced by these agents as measured by a chromium-release 
assay. Immunocytochemical analysis and cytofiuorometric measurement of glial fibrillary acidic protein 
(GFAP) staining in the treated cultures revealed an increase in GFAP staining over control cultures. In contrast 
to the response of glioma cells, nonmalignant human adult astrocytes treated with the PKC activators responded 
by increasing their proliferation rate. 
The authors postulate that the diametrically opposed effects of PKC activators on nonmalignant astrocytes 
versus glioma growth may be due to a high intrinsic PKC activity in glioma cells, with resultant down-
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I NTERNAL signal transduction mechanisms are cen-tral in the molecular control of cell growth. One such regulator is known to be the protein kinase-C 
(PKC) system. This enzyme complex is part of a family 
of proteins that function in the capacity of translating 
an externally recognized signal into altered cellular 
function by systems of regulatory and catalytic proteins, 
broadly referred to as "second-messenger" systems.26 In 
the case of PKC, when a ligand binds to appropriate 
receptors on the cell surface, through the mediation of 
G proteins membrane-associated inositol phospholipids 
are hydrolyzed, producing diacylglycerol and inositol 
phosphates. It is thought that the primary effect of the 
diacylglycerol liberated is the activation of PKC which 
in turn phosphorylates a range of cellular proteins. 18 
Protein kinase-C is a calcium and phospholipid-de-
pendent kinase which is very active in central nervous 
system tissue. 14 Its myriad of effects in different cell 
types l9 include cell differentiation and process forma-
tion in 0ligodendrocytes3o and proliferation of normal 
human fetal astrocytes.29 
A well-appreciated clinical phenomenon is an accel-
eration in the growth rate of an existing low-grade 
glioma in vivo coexistent with a change in its histolog-
ical grade.22,23 One hypothesis for this change implicates 
induction of an autocrine growth promotory system in 
these tumors; in this paradigm, a likely mechanism 
would be that this occurs by way of a signal transduc-
tion mechanism at the cellular level. Previous work in 
our laboratory has shown that activators of PKC are 
mitogenic for nonmalignant human fetal astrocytes.29 
As gliomas are of astrocytic origin, this study was 
undertaken to assess the effects of PKC modulators on 
the growth and differentiation of established human 
glioma cell lines in vitro. We show here that PKC 
activators result in a decrease in the proliferation rate 
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of human glioma cells. In contrast, and paralleling the 
observation made with nonmalignant fetal astrocytes, 
human adult astrocytes were induced to proliferate by 
activators of the PKC system. 
Materials and Methods 
Glioma Cell Lines 
Glioma cell lines U 563 MG and A 172* were used in 
this study: they are previously characterized lines estab-
lished elsewhere. 6,9,2t These lines were passaged regu-
larly (consisting of gentle trypsinization at 0.05% for 
10 minutes followed by serum inactivation of trypsin 
and then repeated washes with phosphate-buffered sa-
line (PBS) and replating) and maintained in 25-sq cm 
tissue culture flasks, in medium consisting of Eagle's 
minimum essential medium (MEM) supplemented 
with 10% bovine fetal serum (FCS), gentamicin (20 lig/ 
ml), glutamine, pyruvate (I mM), dextrose (0.1 %), and 
essential amino acids buffered to a pH of 7.0.t Cells 
were grown at 37% in a humidified 5% CO2 incubator. 
Astrocyte Cell Cultures 
Nonmalignant human brain tissue was obtained 
from young adults (mean age 24.5 years) during surgical 
resection to ameliorate intractable epilepsy. Tissue ad-
jacent to the epileptogenic focus was removed by ultra-
sonic aspiration.* The origin of the tissue was the 
corpus callosum (one case) or the temporal lobe (three 
cases). For cell isolation, meninges and visible blood 
vessels were removed and brain tissue was cut into 
cubes of I cu mm or less. Viable dissociated cells were 
then obtained using a previously established protocol 
involving trypsin digestion and Percoll§ centrifuga-
tion. t0.30 Cells were suspended in feeding medium and 
placed in Falcon flasks of 50 ml capacity for 24 hours, 
after which the floating cells (mostly oligodendrocytes) 
were removed for other studies. Adherent cells (mostly 
astrocytes and microglia) were left undisturbed and al-
lowed to differentiate. Seven days later, these cells were 
removed from their flasks by 0.05% trypsin and seeded 
on 9-mm plastic coverslips coated with poly-I-Iysinell 
at a density of 5 x 104 cells per coverslip. By immu-
nohistochemical identification, the majority of the cells 
were glial fibrillary acidic protein (GFAP)-positive as-
trocytes and presumed microglial cells (leu-M5-positive, 
avid bead ingestion, and MHC class II expression). The 
feeding medium was Eagle's MEM supplemented with 
5% FCS, 20 J.tg/ml gentamicin, and 0.1 % dextrose. The 
cultures used in this study ranged in age from 2 to 4 
weeks postdissociation. 
* Glioma cells provided by courtesy of V. P. Collins, M.D., 
Ludwig Institute of Cancer Research, Stockholm, Sweden. 
t All medium constituents obtained from GIBCO, Grand 
Island, New York. 
* Ultrasonic aspirator manufactured by Cavitron Surgical 
Systems, Inc., Stamford, Connecticut. 
§ Percoll manufactured by Pharmacia, Uppsala, Sweden. 
II Poly-I-lysine supplied by Sigma Chemical Co., St. Louis, 
Missouri. 
J. Neurosurg. / Volume 73/ October. 1990 
Incubation of Glioma Lines with Protein Kinase-C 
Modulators 
Following passage, the cell lines were seeded at a 
density of 104 cells in 30 iii of medium on 12-mm 
plastic coverslips placed in 24-well culture plates. The 
coverslips were previously coated with 10 lig/ml poly-
I-lysine to facilitate cell adherence. Twelve hours later, 
after adequate time for cells to adhere to the coverslips, 
the wells were flooded with I ml of medium. Each 
modulator* was then added to the wells at predeter-
mined concentrations in replicates of three: I) 4-beta-
phorbol-12, 13-dibutyrate (PDB) and phorbol-12-myr-
istate-13-acetate (PMA), which are phorbol esters and 
activators of PKC, were administered at doses of I, 10, 
and 100 nM each; 2) 4-alpha-phorbol-12,13-dideca-
noate (a-POD), a phorbol ester which binds but does 
not activate the enzyme was used at concentrations of 
10 and 100 nM; and 3) diacylglycerol (l,2-dioctanoyl-
sn-glycerol), an endogenous activator of the PKC en-
zyme, was used at concentration of 10 liM. The syn-
thetic activator SC-9 t7t was diluted in eth~nol and 
added to supplemented medium to a final concentra-
tion of 10 and 50 liM. Medium was changed in each 
well on the 4th day in vitro to prevent nutrient-limited 
growth. 
Tritiated Thymidine Uptake 
At specified intervals, wells were pulsed for a period 
of 5 hours prior to harvest with 1 liCi 3H-thymidine/ 
ml. The coverslips with adherent cells were then washed 
four times with PBS and placed in vials containing 5 
ml of scintillation fluid (Cytoscint), for determination 
in a beta counter. To demonstrate that uptake of 3H_ 
thymidine into cells is a reliable index of deoxyribo-
nucleic acid (DNA) synthesis, a control experiment was 
performed in which synthesis of DNA in the glioma 
cells was stopped by treating the cells with 50 J.tg/ml of 
mitomycin-C for 30 minutes; the cells were then washed 
four times with fresh medium and pulsed as above with 
3H-thymidine. Resulting background cell counts were 
negligible. 
Chromium-Release Assay 
Following passage, cells were plated at 2 x 104 per 
well in replicates of four in a 96-well flat-bottomed 
plate. After 24 hours, the wells were gently washed with 
PBS and StCr was added in a concentration of I /LCi/ 
100 /LI of culture medium to each well. The cells were 
then incubated for a period of 12 hours to allow for 
adequate incorporation of StCr, after which the wells 
were gently washed three times with medium to remove 
the free label. The cells were then left for the first 30 
minutes for spontaneous release to occur. Medium was 
removed, and the modulators were added to the wells 
* POB, PMA, a-POD, and diacylglycerol obtained from 
Sigma Chemical Co., St. Louis, Missouri. 














































































0 - 0 Con"'" 
.- .PW. 1nW 
d-.6.PWA 10nW 
... - ... PWA loanw 
0-0 Control 
. - e PWAlnJr.1 
6-.o.PWA ,any 
6. - 6o PMA l00n.W 
Days in Vitro 
o - oContral 
. - e SC-iSOJM 
0-0 Con"'" 
. - e a-POD lOn .. 
6 - 6 a-POD 100nY 















. - e . - PDO 1()n.),1 
tJ.-i:J. a- PDO lOOnN Al72 
O+----+----r---;----;----+----+--~ 
o 
Doys in Vitro 
at the maximum concentrations used in this experi-
ment. The agents were incubated for 5 hours, after 
which supernatant was removed and radioactivity was 
measured on a gamma counter (measurement of cyto-
toxic cell lysis). Then 100 1'1 of 5 N NaOH was added 
596 















7000 O - OContn>! 
. - . POe 1nlll 
6000 6 - 6P0810nW 
































0 - 0 Control 
.-. CW;10~ U563 
0 
O - OCMtl"Dl 
. - e OAC 101M A172 
0 
Days In Vitro 
FIG. I. The effect of various modulators of PKC on the 
rate of thymidine incorporation in vitro. The addition of the 
phorbol ester PMA decreases thymidine incorporation in both 
cultures in a dose-related fashion (A). Similarly, the phorbol 
ester PDB (B) and the synthetic nonphorbol ester activator 
SC-9 (C) decrease the rate of incorporation. Diacylglycerol, 
an endogenous activator of PKC with a transient existence, 
decreases the rate of incorporation over the first 48 hours of 
addition (0), after which the rate approximates control levels . 
Addition of the inactive phorboJ ester a-POD demonstrates 
no significant decrease in growth rate compared to control 
preparations (E). 
for 15 minutes to lyse the remaining cells, and super-
natant was removed and counted for radioactivity 
(maximum releasable value). 
Immunohistochemistry 
Glial Fibrillary Acidic Protein Staining. Live cells 
were seeded on 12-mm plastic coverslips and prepared 
as outlined above. The cells were first fixed with 95% 
ethanol-5% acetic acid mixture at -20·C for 15 minutes 
and, after rehydration with PBS, were incubated with 
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rat anti-GFAP monoclonal antibody (2.2BlO)16 for 30 
minutes at room temperature. Following this, coverslips 
were washed with PBS and then incubated with goat 
anti-rat immunoglobulin conjugated to rhodamine* for 
another 30 minutes. The coverslips were again washed 
with PBS and wet-mounted on glass coverslips with 
glycerol-PBS. Negative control tests for staining were 
performed on the glioma cells by omitting the primary 
antibody step; positive control tests for the GF AP-
specific monoclonal antibody were the simultaneous 
staining of nonmalignant astrocyte cultures. The slides 
were viewed with a fluorescence microscope. 
Ki-67 Staining. The Ki-67 antibody was utilized to 
confirm the modulation of glioma growth as measured 
by 3H-thymidine incorporation. Ki-67 is a murine mon-
oclonal antibody directed against a nuclear antigen 
expressed in proliferating cells in the GJ, S, G2, and M 
phases of the cell cycle and is shown to correlate with 
the proliferation rate of malignant gliomas. 31 The cells 
were plated and fixed following the aforementioned 
protocol. After fixation, the Ki-67 antibody (diluted 
1 :SO)§ was placed in 2S-~1 volumes on the coverslips 
for 30 minutes at room temperature. The coverslips 
were then washed and incubated with a secondary goat 
anti-mouse antibody conjugated to rhodamine. The 
coverslips were mounted and viewed as described 
above. 
Cytofluorometry 
For purposes of determination of cellular GF AP 
content, cells were propagated in Petri dishes for a 
period of 3 days with the corresponding PKC modula-
tor (100 nM PDB or 100 nM PMA). At this time, the 
cells were removed using gentle trypsinization (O.OS% 
for 10 minutes) and washed three times in PBS after 
inactivation of the trypsin with FCS. The cells were 
fixed for a period of 30 minutes in a solution of 9S% 
ethanol-S% acetic acid at - 20·C. Immunocytochemical 
GF AP staining was then performed in 1.8-ml Ependorf 
tubes using 30 ~l of rat anti-GF AP primary antibody 
(volume to achieve saturation of antigen) followed with 
equivalent volumes of goat anti-rat secondary antibody 
conjugated with fluorescein isothiocyanate. Each stain 
was followed by three washes with PBS. The samples 
were analyzed with a Fluorescent Activated Cell Sorter 
flow cytometer to quantitate the amount of immuno-
fluorescence specifically related to GFAP staining. Gat-
ing for acquisition of single cells was performed and 
SOOO events were acquired from each culture for GF AP 
fluorescence analysis. 
Analysis of Proliferation of Nonmalignant 
Astrocytes 
Since the nonmalignant cultures contained a mixture 
t Rhodamine obtained from Cappel, West Chester, Penn-
sylvania. 
§ Ki-67 antibody supplied by Dakopatts. Copenhagen, 
Denmark. 
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of cell types, 3H-thymidine incorporation would not 
have yielded information as to the cell type that incor-
porated the label. For this reason, a double immunoflu-
orescence technique that allows direct visualization of 
the cell type that has incorporated the proliferation 
label (bromodeoxyuridine or BUdR) was used. Cells 
were incubated with test agents (PDB, PMA, and a-
PDD) for 4 days, and 10 ~M BUdR was added during 
the last 48 hours to allow proliferating cells to incor-
porate this label. The cells were then immunostained 
using antibodies to GFAP and BUdR by a method that 
has been described in detail elsewhereY·28 The results 
from the four primary astrocyte cultures were pooled. 
Results 
Effects of PKC Modulators on Thymidine Uptake 
in Glioma Lines 
In the tumor lines US63 MG and Al72, after 48 
hours in culture with PDB, the rate of proliferation as 
assessed by 3H-thymidine uptake decreased to 29% and 
46% of controls, respectively (Fig. 1). This decreased 
uptake persisted throughout the duration of the study 
(6 days), after which the control cell cultures were 
monolayers and exhibited density-dependent reduced 
growth rates. Similarly, the administration of another 
biologically active phorbol ester, PMA, produced a 
dose-related reduction of proliferation to 24% and 3S% 
of controls. The synthetic nonphorbol ester activator 
(SC-9) exhibited a more pronounced decrease in thy-
midine incorporation, to 12% and 18% of controls in 
the same period. Diacylglycerol, an endogenous acti-
vator of PKC, transiently decreased the proliferation, 
in concordance with its short-lived existence in vivo. 
Conversely, the addition of a phorbol ester, a-PDD, 
which binds but does not activate the enzyme, had no 
effect on the proliferation rate. 
Immunocytochemistry performed with the mono-
clonal antibody Ki-67 revealed a marked diminution 
in fluorescent staining of both Al72 and US63 MG 
following incubation with PMA for a period of 36 
hours, supporting evidence that the decrease in thymi-
dine incorporation with treatment truly reflected a de-
crease in cell proliferation. 
PKC Modulators and Cytotoxicity 
A chromium-release assay was performed to deter-
mine if the diminution of thymidine uptake observed 
was due to direct cytolysis of glioma cells induced by 
modulators of the PKC system. Results of the assay 
revealed that, at the dosages that decreased prolifera-
tion, there was no direct cytotoxicity of these agents 
(that is, no increase in percent specific lysis compared 
to media control). Ethanol 30% was used as a positive 
assay control. 
PKC Activity and GFAP Staining 
Four days following the administration of the phor-
bol esters PDB and PMA, the intensity of GF AP im-
597 
munolabeling of glioma cultures was qualitatively com-
pared with the control preparations. These results show 
that the immunostaining of GF AP appeared to increase 
in the V563 MG cells exposed to the phorbol ester 
(Fig. 2). 
For purposes of quantitation of the change in GF AP 
immunostaining observed, cytofluorometric analysis 
was performed 4 days after the addition of the PKC 
stimulators. These results are summarized in Fig. 3. 
Incubation in 100 nM of the phorbol ester PMA pro-
duced a significant increase in the anti-GF AP immu-
nofluorescence over controls in glioma line V563 MG. 
Similarly, POB produced a smaller increase in the same 
cell line. In glioma line Al72, the quantitative increase 
in anti-GF AP staining following treatment with 100 
nM PMA as reflected by increased immunofluorescence 
was more pronounced. 
PKC Modulators and Proliferation of 
Nonmalignant Astrocytes 
In contrast to the results obtained with the glioma 
cells, phorbol esters that activate PKC caused increased 
proliferation rate of nonmalignant astrocytes. As shown 
FIG. 2. Immunocytochemical staining of glial fibrillary 
acidic protein (GFAP), x 550. The culture of U563 MG 
following 96 hours in culture with 100 nM PMA (A) demon-
strates markedly increased staining of GF AP in comparison 
to the control preparation (B). 
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in Fig. 4, POB exerted a dose-dependent effect such 
that, at 100 nM, a proliferation index of 7 was obtained 
(that is, a sevenfold increase over controls was found). 
At 100 nM, PMA was similarly effective, while the 
inactive phorbol ester a-POO did not elicit a prolifera-
tive response. An example of nonmalignant astrocytes 
incorporating BVdR is shown in Fig. 5. 
Discussion 
Phorbol esters are the classic pharmacological acti-
vators of PKC.3,15,19 In addition to their historical role 
as second-stage tumor promoters, 1,2 they are mitogenic 
for many cell types,8 including normal human fetal 
astrocytes,29 and (as shown in Fig. 4) for biopsy-derived 
nonmalignant human adult astrocytes. In contrast, gli-
oma cells demonstrate a dose-related decrease in pro-
liferation after treatment with PKC activators. That the 
effects of PMA and POB on glioma cells are mediated 
by the PKC system is supported by the ability of the 
nonphorbol PKC activator SC-9 to decrease the prolif-
eration rate and by the failure of a-POO (which binds 
but does not stimulate PKC) to duplicate this effect. 
Further support comes from the time course of action 
of diacylglycerol, which decreased the 3H-thymidine 
incorporation transiently in concordance with its more 
rapid metabolism to inactive compounds. 
Several different mechanisms could potentially ac-
count for the observed PKC-regulated growth of 
gliomas. If intrinsic PKC activity of gliomas were ele-
vated compared to nonmalignant glia, persistent stim-
ulation of PKC by phorbol esters could down-regulate 
such elevated enzyme activity, as reported in other cell 
types.4,5,20,24 This hypothesis may help to explain the 
paradoxical effect of POB and PMA on the proliferation 
of slower growing normal astrocytes compared to the 
suppression of thymidine incorporation by glioma cells 
in this study. 
Another interpretation would be that the response of 
glioma cells to phorbol esters represents a state of in-
creased differentiation of these cell lines, with secondary 
slowing of the rate of cell division. That an increased 
state of differentiation of glioma lines occurs after 
treatment of phorbol esters in this study is supported 
by the observed increase in GF AP content as analyzed 
by immunohistochemistry and cytofluorometry. An in-
termediate filament, GF AP is characteristic of astro-
cytes and tumors of astrocytic lineage. The quantity of 
GFAP staining in astrocytic tumors is often inversely 
proportional to the degree of anaplasia, and indeed the 
highly malignant glioblastoma multiforme may be 
GFAP-negative. 12,13 Gliomas often lose their expression 
of GF AP with repeated passages in tissue culture.6 In 
further support of glioma cell differentiation is the 
report by Colombatti, et al.,7 of growth inhibition and 
concordant decrease in surface tumor-associated anti-
gen in one glioma cell line after phorbol ester treatment. 
Phorbol esters have been shown to induce differentia-
tion of a murine reticulum cell sarcoma line to phe-
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FIG. 3. Histogram plots showing fluorocytochemical analysis of glial fibrillary acidic protein (GFAP) 
staining. x axis: logarithmic fluorescence units. A: Culture Al 72 control (solid line) and after incubation 
with 100 nM PMA (dotted histogram) demonstrating a shift in fluorescent intensity related to increased 
GFAP staining. B: Similar display of the U563 MG control and after incubation with the phorbol ester 
showing increased immunofluorescence to a lesser magnitude. 
notypically mimic macrophages,25 increase neurite for-
mation in neuroblastoma (an index of neuronal differ-
entiation), II and facilitate process development in 
human adult 0ligodendrocytes.3o Our findings of a de-
crease in proliferation rate of gliomas after treatment 
with the PKC activators as early as 30 minutes (earliest 
time point measured) after drug administration (unpub-
lished results), would favor the fact that the increased 
differentiation of these cells is secondary to a decrease 
in proliferation. 
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FIG. 4. Response of nonmalignant human adult astrocytes 
to protein kinase-C modulators. Values are means + standard 
error of the mean, with the number of coverslips analyzed 
shown in parentheses. An average of 100 glial fibrillary acidic 
protein (GFAP)-positive astrocytes were counted on each 
coverslip. The percent of astrocytes that incorporated the 
bromodeoxyuridine (BUdR) in each test culture was divided 
by results from appropriate controls to give the proliferation 
index (therefore, a value of 1 indicates no proliferative re-
sponse). On average, over the 48-hour pulse with BUdR, 3% 
to 5% of control astrocytes incorporated BUdR. Asterisks 
indicate values significantly different from control cultures 
using a one-way analysis of variance with Duncan's multiple 
comparison, p = 0.05. All analyses were performed blind on 
coded specimens. 
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FIG. 5. Immunohistochemical technique of determining 
proliferating astrocytes, x 540. Double labeling using glial 
fibrillary acidic protein (GFAP) alone (A) or with bromode-
oxyuridine staining (B) enables quantitation of GF AP-pos-
itive cells that are actively dividing within the same field. 
Arrows demarcate two such double-labeled cells. 
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In conclusion, in contrast to the response of non-
malignant human fetal or adult astrocytes, glioma cells 
exhibited a decrease in the proliferation rate when 
treated with activators of the PKC system. We are 
presently attempting to correlate this response to the 
intrinsic PKC enzyme activity of glioma cells and to 
ascertain if a particular isoform of the PKC enzyme is 
present within such cells. 
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